- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Epilepsy
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Brivaracetam – November 2019
Brivaracetam: Tablet 25 mg, Tablet 50 mg, Tablet 75 mg, Tablet 100 mg, Oral solution 10mg per mL, 300 mL; Briviact®
Last updated
6 March 2020